0187: Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities

Shalvi Parikh¹, Monica Messina¹, Shivani Garg¹, Sancia Ferguson², Edmond Ramly³, Andrea Gilmore-Bykovskyi⁴, Katrina Phelps⁵ and Christie M. Bartels⁶, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, Madison, WI, ³Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵School of Nursing, University of Wisconsin-Madison, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI

Background/Purpose: Systemic lupus erythematosus (SLE) care and outcomes are associated with significant racial and socioeconomic disparities in the US, particularly among young Black and Hispanic/Latina women. We previously identified disparities, including gaps in SLE retention in care (defined as a rheumatology clinic visit or lupus-specific lab test every 6 months) and hydroxychloroquine (HCQ) use and adherence. We sought to address these modifiable gaps in SLE care by adapting intervention approaches from other chronic diseases. We engaged patients and healthcare community stakeholders to garner input to prioritize actionable steps and intervention strategies to reduce disparities in SLE retention in care and HCQ use to improve outcomes and equity.

Methods: We recruited SLE experts and stakeholders, including patients, providers, and advocates (State Public Health Department, Lupus Foundation, and the American College of Rheumatology) to adapt intervention strategies from other chronic conditions to be tested in SLE. The patient advisory board (PAB; n=8) included patients with SLE representing racial, geographic, age, and sex diversity (Figure 1). PAB insights were presented to a healthcare advisory board (HAB; n=12) of 6 rheumatologists, 2 rheumatology nurses, 2 primary care providers, and 2 patient advocates (Figure 1). The HAB reviewed prior findings on SLE care gaps and evaluated proven interventions for a pilot. Each group had 3 virtual meetings of 90 minutes (total=6) scheduled to be alternating and iterative. Sessions were audio-video recorded and analyzed using direct content analysis with NVivo software (Melbourne, AU).

Results: The PAB discussed several barriers to SLE retention in care and HCQ, categorized as: labs, visits, and medication adherence (see Table 1 quotes and meta-themes). Facilitators were similarly identified and grouped (Table 1). The main evidence-based interventions considered were electronic health record (EHR) workbench decision support (e.g., HIV FastTrack) that cues staff action upon missed visits and labs; shared decision making; and patient navigators (Table 2). All HAB members and 5 of 8 PAB members supported implementing EHR workbench decision support. PAB and HAB members also suggested including a patient navigator as a supplement to answer patient questions and address challenges in scheduling, medication dosing, and cost barriers, among others. Among HAB members, 8 of 12 recommended EHR workbench decision support as high-impact and low-effort; while 7 of 12 rated patient navigator as high-impact but high-effort. Many discussed that the two could be complementary, recommending EHR workbench decision support first, followed by patient navigator. Indicators for additional support recommended by HAB members were social determinants of health, missed labs or clinic visits, and frequent acute care.

Conclusion: Patient and healthcare stakeholders endorsed implementing EHR workbench decision support, potentially followed by a patient navigator, to reduce disparities and care gaps in SLE. An external advisory board of national SLE leaders is advising scalability for a larger study, and the findings will inform addressing key gaps and unique factors in SLE.








S. Parikh: None; M. Messina: None; S. Garg: None; S. Ferguson: None; E. Ramly: None; A. Gilmore-Bykovskyi: None; K. Phelps: None; C. Bartels: Pfizer, 5.